🔬🧬 Oncology Updates: VORANIGO CHMP Nod, Tagrisso OS Boost, KRAS G12D Fast Track and More
Â
From Europe’s first IDH-mutant glioma therapy to long-term bladder cancer data and the latest in EGFR-targeted NSCLC strategies—this week’s oncology roundup captures the pivotal developments transforming global cancer treatment.
💡 Key Highlights This Week:
✅ Servier’s VORANIGO receives positive CHMP opinion for IDH-mutant Grade 2 glioma based on INDIGO Phase 3 data
✅ Tagrisso + chemo significantly improves OS in EGFR-mutated NSCLC per FLAURA2 Phase 3 trial
🧬 ArriVent completes enrollment for FURVENT Phase 3 trial evaluating firmonertinib in EGFR exon20 insertion NSCLC
🧪 Roche’s Itovebi approved in EU for advanced PIK3CA-mutated breast cancer after doubling PFS in INAVO120 trial
🚀 Verastem receives FDA Fast Track designation for KRAS G12D inhibitor VS-7375, addressing 37% of pancreatic cancers
🇪🇺 Candel’s CAN-2409 gains EMA Orphan Designation; median OS of 31.4 months and immune activation in pancreatic cancer
🧠Akeso launches Phase 3 HARMONi-GI2 study of Ivonescimab for metastatic pancreatic cancer using PD-1/VEGF bispecific
✅ CABOMETYX approved in EU for all subtypes of advanced neuroendocrine tumors following CABINET Phase 3 success
💧 UroGen’s ZUSDURI shows 3.5-year duration of response and 2-year event-free period in long-term bladder cancer study
🇨🇦 KEYTRUDA + chemoradiotherapy approved in Canada for Stage III–IVA cervical cancer based on KEYNOTE-A18 trial
🎯 Whether you’re following precision oncology, immunotherapy combinations, or regulatory milestones—this episode delivers the need-to-know insights powering cancer care innovation.
📢 Stay Ahead in Oncology Research!
✅ Like, share, and subscribe for weekly updates on oncology breakthroughs and cancer immunotherapy
#Oncology #CancerResearch #Immunotherapy #ClinicalTrials #NSCLC #EGFR #KRAS #Glioma #BreastCancer #PancreaticCancer #CervicalCancer #NeuroendocrineTumors #PIK3CA #PD1 #VEGF #BiotechNews #LucidQuest #PharmaInnovation #BladderCancer #HealthcareUpdates #OncologyApprovals #OncologyBreakthroughs